Anti-yo antibody-positve cerebellar degeneration associated with endometrial carcinoma: Case report and review of the literature

Clinical Oncology

Volumn 13, Issue 6, 2001, Pages 476-479

  Brock, S ^a   Illidge, T ^a,c   Ellison, D ^b   Frankel, J ^b   Davis, C ^b  

^a Wessex Cancer Trust   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Anti Yo antibody; Endometrial cancer; Paraneoplastic cerebellar degeneration

Indexed keywords

AUTOANTIBODY; DEXAMETHASONE; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG; YO ANTIBODY;

AGED; ARTICLE; AUTOPSY; CASE REPORT; CEREBELLUM DEGENERATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; PARANEOPLASTIC NEUROPATHY; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035685818     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.9318     Document Type: Article

References (28)

1. Antineural autoantibodies in patients with paraneoplastic cerebellar degeneration
2. Paraneoplastic cerebellar degeneration. 1. A clinical analysis of 55 anti-Yo antibody positive patients
3. Paraneoplastic cerebellar degeneration: A clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies
4. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma
5. Paraneoplastic cerebellar degeneration. Case report and review of the literature
6. Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: Case report and review of the literature
7. Autoimmune central nervous system paraneoplastic disorders: Mechanisms, diagnosis and therapeutic options
8. Cancer and the nervous system: The neurological manifestations of systemic disease
9. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume
10. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies
11. Paraneoplastic cerebellar degeneration with anti-Yo antibody in a man
12. Anti-Yo associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin
13. The case for descriptive generic nomenclature: Clarification of immunostaining criteria for PCA-1, ANNA-1 and ANNA-2 autoantibodies
14. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration
15. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes
16. Pathogenesis of central nervous system paraneoplastic syndrome
17. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: A long term survey of ovarian cancer patients
18. Selective expression of Purkinje cell antigens in tumour tissue from patients with paraneoplastic cerebellar degeneration
19. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: Report on the workshop to the fourth meeting of the International Society of Neuro-immunology on paraneoplastic neurological disease
20. Yo sera recognise a family of DNA binding proteins
21. Effect of intravenous injection of anti-Purkinje cell antibody (anti-Yo) in a guinea pig model
22. Tumour specific killer cells in paraneoplastic cerebellar degeneration
23. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody
24. Paraneoplastic cerebellar degeneration: Clinical-immunological correlations
25. A patient with breast cancer and paraneoplastic cerebellar syndrome associated with anti-Purkinje cell antibodies: Response to CMF chemotherapy
26. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration
27. Intravenous immunoglobulin in the therapy of paraneoplastic neurological disorders
28. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies